Barclays PLC Purchases 72,591 Shares of Liquidia Co. (NASDAQ:LQDA)

Barclays PLC boosted its position in Liquidia Co. (NASDAQ:LQDA) by 265.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 99,984 shares of the company’s stock after acquiring an additional 72,591 shares during the period. Barclays PLC owned 0.12% of Liquidia worth $999,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Quest Partners LLC acquired a new position in Liquidia during the 2nd quarter valued at about $27,000. Clear Harbor Asset Management LLC acquired a new position in Liquidia in the third quarter valued at approximately $100,000. Signaturefd LLC boosted its stake in Liquidia by 38,400.0% in the third quarter. Signaturefd LLC now owns 10,010 shares of the company’s stock valued at $100,000 after acquiring an additional 9,984 shares during the last quarter. Ballentine Partners LLC acquired a new stake in Liquidia during the 3rd quarter worth $110,000. Finally, Whitcomb & Hess Inc. raised its position in shares of Liquidia by 10.2% during the 3rd quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company’s stock valued at $116,000 after acquiring an additional 1,074 shares during the last quarter. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Roger Jeffs sold 22,343 shares of the business’s stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total value of $263,200.54. Following the sale, the chief executive officer now owns 1,019,177 shares of the company’s stock, valued at $12,005,905.06. The trade was a 2.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Michael Kaseta sold 23,370 shares of the firm’s stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $275,298.60. Following the completion of the transaction, the chief financial officer now directly owns 401,755 shares of the company’s stock, valued at approximately $4,732,673.90. This trade represents a 5.50 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 73,581 shares of company stock worth $864,565 over the last three months. Corporate insiders own 30.10% of the company’s stock.

Liquidia Trading Down 3.4 %

LQDA opened at $11.36 on Wednesday. The firm’s fifty day simple moving average is $11.20 and its 200 day simple moving average is $11.01. The stock has a market capitalization of $961.48 million, a P/E ratio of -6.97 and a beta of 0.23. Liquidia Co. has a 12 month low of $8.26 and a 12 month high of $16.99.

Analysts Set New Price Targets

Several research firms have recently issued reports on LQDA. Wells Fargo & Company initiated coverage on Liquidia in a research report on Friday, December 20th. They issued an “overweight” rating and a $20.00 price target on the stock. Lifesci Capital began coverage on shares of Liquidia in a report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $29.00 target price on shares of Liquidia in a research note on Thursday, November 14th. Needham & Company LLC reissued a “buy” rating and set a $19.00 price target on shares of Liquidia in a research report on Thursday, January 9th. Finally, Scotiabank assumed coverage on shares of Liquidia in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price objective for the company. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Liquidia has a consensus rating of “Buy” and a consensus target price of $25.38.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).